QRICH1-Mediated ER Stress Drives HBV-Induced HMGB1 Secretion

Study Background and Research Question

Chronic hepatitis B virus (HBV) infection remains a major cause of progressive hepatic fibrosis and, ultimately, cirrhosis and hepatocellular carcinoma worldwide. A central feature of this progression is the persistent activation of inflammatory pathways and fibrogenic signals in hepatocytes and non-parenchymal cells. High mobility group box 1 (HMGB1), normally a nuclear protein, is secreted during cellular stress or injury and acts as a damage-associated molecular pattern (DAMP), amplifying inflammation and fibrosis in the liver. However, the molecular mechanisms underpinning HMGB1 secretion in HBV-induced hepatic injury have not been fully elucidated. Recent evidence implicates endoplasmic reticulum (ER) stress as a driver of hepatic fibrogenesis, but the key effectors linking ER stress to HMGB1 secretion, especially in the context of HBV infection, were previously unclear (DOI:10.1016/j.imbio.2025.152913).

Key Innovation from the Reference Study

The referenced study provides the first direct evidence that glutamine-rich 1 (QRICH1), a transcription factor and critical effector of ER stress, is upregulated in HBV-infected hepatocytes and serves as a molecular bridge between ER stress and HMGB1-driven fibrogenic signaling. The authors demonstrate that QRICH1 not only enhances overall ER stress but also directly promotes HMGB1 transcription, acetylation, cytoplasmic translocation, and eventual secretion. This mechanistic insight positions QRICH1 as both a marker and potential regulator of fibrogenic response in HBV-associated liver disease (DOI:10.1016/j.imbio.2025.152913).

Methods and Experimental Design Insights

To dissect the interplay between QRICH1, ER stress, and HMGB1 secretion, the researchers employed a multifaceted approach:

• In vivo models: Chronic recombinant cccDNA (rcccDNA) mouse models simulating persistent HBV infection and hepatic fibrosis.
• Clinical specimens: Liver tissue and serum from patients with chronic hepatitis B (CHB) and varying degrees of fibrosis, sourced from Zhongshan Hospital, Fudan University.
• Immunohistochemistry and staining: Detection of QRICH1 and HMGB1 expression levels, and liver collagen deposition via Sirius red and Masson's trichrome staining.
• Protein and gene expression assays: Western blotting and qRT-PCR to assess HMGB1 cyto-translocation, with serum HMGB1 and liver injury markers quantified by ELISA.

These methods enabled precise correlation of QRICH1 and HMGB1 levels with fibrotic progression and ER stress status in both animal and human samples (DOI:10.1016/j.imbio.2025.152913).

Core Findings and Why They Matter

The study's principal findings are as follows:

• Elevated QRICH1 and HMGB1 in Fibrosis: Both rcccDNA mice with ER stress activation and CHB patients with severe fibrosis exhibited significantly increased QRICH1 expression and HMGB1 secretion. These two markers were positively correlated in diseased states (DOI:10.1016/j.imbio.2025.152913).
• Mechanistic Link via SIRT6 and Acetylation: HBV infection modulates Sirtuin6 (SIRT6) expression, which in turn regulates HMGB1 acetylation and translocation from the nucleus to the cytoplasm—an essential step for HMGB1 secretion.
• QRICH1 Amplifies HBV-Driven HMGB1 Secretion: QRICH1 enhances transcription and subsequent cytoplasmic translocation of HMGB1, thereby intensifying the pro-fibrotic DAMP signaling in hepatocytes under HBV infection.

These mechanistic insights clarify how ER stress and QRICH1 synergize with HBV infection to drive fibrogenic signaling, providing targets for therapeutic intervention in hepatic fibrosis (DOI:10.1016/j.imbio.2025.152913).

Protocol Parameters

• assay | Sirius red staining | qualitative/quantitative | assesses liver collagen deposition in fibrosis models | paper
• assay | ELISA for HMGB1 | ng/mL (serum) | quantifies HMGB1 secretion and correlates with liver injury | paper
• assay | Immunohistochemistry for QRICH1, HMGB1 | % positive cells / intensity score | tracks expression changes in tissue | paper
• assay | qRT-PCR for HMGB1 mRNA | fold change | measures transcriptional upregulation | paper
• assay | Western blot for cytoplasmic/nuclear HMGB1 | band intensity (relative) | determines translocation dynamics | paper
• assay | Use of a growth factor supplement for cultured cells (e.g., bovine insulin) | 10 µg/mL (workflow_recommendation) | supports hepatocyte viability and experimental reproducibility in fibrogenesis models | workflow_recommendation

Comparison with Existing Internal Articles

Several recent reviews and scenario-driven analyses have explored the intersection of cell culture optimization, peptide hormone supplementation, and mechanistic modeling of liver disease:

• The article "Bovine Insulin: Molecular Insights for Metabolic and ER Stress Pathways" specifically discusses how insulin from bovine pancreas modulates the insulin signaling pathway and ER homeostasis, offering a biochemical bridge to the ER stress mechanisms highlighted in the QRICH1 study. This context reinforces the relevance of metabolic regulators in modeling fibrosis-related cellular responses.
• In "Bovine Insulin (SKU A5981): Data-Driven Solutions for Cell Culture", the focus is on practical workflow enhancements, such as using bovine insulin as a cell proliferation enhancer, which can be applied to hepatocyte culture models engaged in mechanistic studies of fibrogenesis.
• The article "Bovine Insulin as a Next-Generation Cell Culture Supplement" contextualizes the use of peptide hormones for cell culture in metabolic research, further supporting the translational application of growth factor supplements in disease modeling.

While none of these articles directly address QRICH1 or HBV-driven HMGB1 secretion, they collectively underscore the importance of reproducible cell culture conditions and metabolic regulation for mechanistic liver disease research.

Limitations and Transferability

The primary limitations of this study stem from the reliance on animal models and ex vivo clinical specimens. While the chronic rcccDNA mouse model recapitulates key features of HBV-induced hepatic fibrosis, differences in viral-host interactions and immune responses between mice and humans may impact the generalizability of findings. Additionally, while QRICH1 is shown to be a central effector, the broader network of ER stress mediators and their interplay with other DAMPs, cytokines, and fibrogenic pathways warrants further investigation. Therapeutic translation will require validation in larger, longitudinal human cohorts and in vitro systems that closely mimic human hepatocyte biology (DOI:10.1016/j.imbio.2025.152913).

Research Support Resources

Researchers seeking to reproduce or extend these mechanistic studies of ER stress, hepatocyte injury, and fibrogenic signaling can benefit from optimized culture workflows. For example, supplementing hepatocyte cultures with Bovine Insulin (SKU A5981) provides a defined growth factor environment, supporting cell proliferation and consistent metabolic responses during experimental modeling of ER stress and fibrosis (workflow_recommendation). APExBIO supplies high-purity insulin from bovine pancreas, accompanied by quality control documentation, and suitable for research use in cell-based assays. For broader context and practical guidance, see recent reviews on bovine insulin in ER stress research and best practices for cell culture supplementation.